Diabetes mellitus and chronic coronary syndrome

Main Article Content

V.A. Serhiyenko
A.A. Serhiyenko


Chronic coronary syndrome is characterized by the development of episodes of ischemia due to an imbalance between needs and blood supply to the myocardium. Such episodes are usual­ly provoked by physical or emotional stress or other stressful situations, but can also occur spontaneously. Angina attacks are a classic manifestation of myocardial ischemia. In some cases, the disease may be asymptomatic for a while and begin immediately with acute coronary syndrome. Chronic coronary syndrome may have a long preclinical period on the background of confirmed coronary athe­rosclerosis. This review analyses the relevant data about the current state of the problem of diabetes mellitus and chronic coronary syndrome. In particular, the issues related to the peculiarities of risk assessment, the main factors causing a very high risk of atherosclerotic cardiovascular diseases; classification, the main characteristics of chronic coronary syndrome and its features in diabetes mellitus; diagnosis of chronic coronary syndrome (dosed physical acti­vity — bicycle ergometry, treadmill test, or stress tests; single-photon emission computed tomography, stress echocardiography; stress cardiac magnetic resonance imaging, positron emission tomography ­using radioactive tracers) were considered. Features of conservative therapy for chronic coronary syndrome against the background of diabetes mellitus (prescription of antiplatelet agents, β-adrenergic receptor blockers, calcium channel blockers, nitrates, angiotensin-converting enzyme inhibitors, myocardial cytoprotectors, statins) were analyzed. Treatment of a patient with a combination of diabetes mellitus and chronic coronary syndrome will be successful only if adequate antidiabetic therapy that is safe in terms of hypoglycemia and possible cardiovascular risks, on the one hand, and metabolically neutral antianginal therapy, on the other, is prescribed. Undoubtedly, it is necessary to pay attention to the correction of risk factors for cardiovascular diseases, hypertension and chronic heart failure.

Article Details

How to Cite
Serhiyenko, V., and A. Serhiyenko. “Diabetes Mellitus and Chronic Coronary Syndrome”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 17, no. 1, Apr. 2021, pp. 43-55, doi:10.22141/2224-0721.17.1.2021.226431.
Literature Review


International Diabetes Federation (IDF). IDF Diabetes Atlas 2019. 9th ed. Available from: https://diabetesatlas.org/en/resources/. Accessed: September 14, 2020.

American Diabetes Association (ADA). 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S103-S123. doi:10.2337/dc19-S010.

Coutiño-Castelán D, Abundes-Velasco A, de los Santos FD, et al. Diabetes and Cardiovascular Disease. In: Rodriguez-Saldana J, editor. The Diabetes Textbook. Basel: Springer, Cham; 2019. doi:10.1007/978-3-030-11815-0_46. 709-730 pp.

Serhiyenko V, Serhiyenko A. Diabetic Cardiac Autonomic Neuropathy. In: Rodriguez-Saldana J, editor. The Diabetes Textbook. Basel: Springer, Cham; 2019. doi:10.1007/978-3-030-11815-0_53. 825-850 pp.

Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S76-99. doi:10.1161/01.cir.0000437740.48606.d1.

Orringer CE, Jacobson TA, Maki KC. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019 Nov-Dec;13(6):860-872. doi:10.1016/j.jacl.2019.10.014.

American Heart Association; American College of Cardiology. 2018 Prevention Guidelines Tool CV Risk Calculator. Available from: http://static.heart.org/riskcalc/app/index.html#!/baseline-risk.

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. doi:10.1016/j.jacc.2018.11.002.

Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-477. doi:10.1093/eurheartj/ehz425.

Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2019 Jun 25;73(24):3153-3167. doi:10.1016/j.jacc.2018.11.005.

Agrawal S, Mehta PK, Bairey Merz CN. Cardiac Syndrome X: Update. Heart Fail Clin. 2016 Jan;12(1):141-56. doi:10.1016/j.hfc.2015.08.012.

Liu A, Wijesurendra RS, Liu JM, et al. Diagnosis of Microvascular Angina Using Cardiac Magnetic Resonance. J Am Coll Cardiol. 2018 Mar 6;71(9):969-979. doi:10.1016/j.jacc.2017.12.046.

Villano A, Lanza GA, Crea F. Microvascular angina: prevalence, pathophysiology and therapy. J Cardiovasc Med (Hagerstown). 2018 Feb;19 Suppl 1:e36-e39. doi:10.2459/JCM.0000000000000638.

Cekirdekci EI, Bugan B. Level of Anxiety and Depression in Cardiac Syndrome X. Med Princ Pract. 2019;28(1):82-86. doi:10.1159/000495109.

Campeau L. Letter: Grading of angina pectoris. Circulation. 1976 Sep;54(3):522-523.

Verbovoy AF, Pashentseva AV, Verbovaya NI. Diabetic macroangiopathy. Ter Arkh. 2019 Oct 15;91(10):139-143. doi:10.26442/00403660.2019.10.000109. (in Russian).

Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003. doi:10.1093/eurheartj/eht296.

Cohn PF. Silent myocardial ischemia: recent developments. Curr Atheroscler Rep. 2005 Mar;7(2):155-163. doi:10.1007/s11883-005-0039-8.

Albus C, Barkhausen J, Fleck E, Haasenritter J, Lindner O, Silber S. The Diagnosis of Chronic Coronary Heart Disease. Dtsch Arztebl Int. 2017 Oct 20;114(42):712-719. doi:10.3238/arztebl.2017.0712.

Su G, Mi S, Tao H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011 Feb 25;10:19. doi:10.1186/1475-2840-10-19.

De Lemos JA, Omland T. Chronic coronary artery disease: a companion to Braunwald’s heart disease. 1st td. Philadelphia, PA: Elsevier; 2018. 520 p.

Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin. 2014 Aug;32(3):439-455. doi:10.1016/j.ccl.2014.04.001.

Arnold SV, Bhatt DL, Barsness GW, et al. Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation. 2020 May 12;141(19):e779-e806. doi:10.1161/CIR.0000000000000766.

Dădârlat A, Zdrenghea D, Pop D. Role of Duke treadmill score in the diagnosis of ischemic heart disease in women. Rom J Intern Med. 2015 Apr-Jun;53(2):146-152. doi:10.1515/rjim-2015-0020.

Salokari E, Laukkanen JA, Lehtimaki T, et al. The Duke treadmill score with bicycle ergometer: Exercise capacity is the most important predictor of cardiovascular mortality. Eur J Prev Cardiol. 2019 Jan;26(2):199-207. doi:10.1177/2047487318804618.

Lohrke J, Frenzel T, Endrikat J, et al. 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. Adv Ther. 2016 Jan;33(1):1-28. doi:10.1007/s12325-015-0275-4.

Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes Dyslipidemia. Diabetes Ther. 2016 Jun;7(2):203-219. doi:10.1007/s13300-016-0167-x.

Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr. Pract. 2017 Apr;23(Suppl 2):1-87. doi:10.4158/EP171764.APPGL.

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):1269-1324. doi:10.1161/HYP.0000000000000066.

Serhiyenko VA, Serhiyenko LM, Serhiyenko AA. Omega-3 polyunsaturated fatty acids in the treatment of diabetic cardiovascular autonomic neuropathy: A review. In: Moore SJ, editor. Omega-3: Dietary sources, biochemistry and impact on human health. New York: Nova Science Publishers; 2017. 79-154 pp.

Kones R, Howell S, Rumana U. n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: Principles, Practices, Pitfalls, and Promises - A Contemporary Review. Med Princ Pract. 2017;26(6):497-508. doi:10.1159/000485837.

Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018 Nov 30;11(11):CD003177. doi:10.1002/14651858.CD003177.pub4.

Bowman L, Mafham M, Wallendszus K, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018 Oct 18;379(16):1540-1550. doi:10.1056/NEJMoa1804989.

Bernasconi AA, Wiest MM, Lavie CJ, Milani RV, Laukkanen JA. Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials. Mayo Clin Proc. 2020 Sep 17:S0025-6196(20)30985-X. doi:10.1016/j.mayocp.2020.08.034.

Gyberg V, De Bacquer D, Kotseva K, et al. Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV--a survey from the European Society of Cardiology. Eur Heart J. 2015 May 14;36(19):1171-1177. doi:10.1093/eurheartj/ehv008.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-1589. doi:10.1056/NEJMoa0806470.

American Diabetes Association. Standards of Medical Care in Diabetes-2017 Abridged for Primary Care Providers. Clin Diabetes. 2017 Jan;35(1):5-26. doi:10.2337/cd16-0067.

Birkeland KI, Jørgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. doi:10.1016/S2213-8587(17)30258-9.

Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018 Aug 31;17(1):122. doi:10.1186/s12933-018-0762-4.

Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-2619. doi:10.1093/eurheartj/ehu278.

Angiolillo DJ, Baber U, Mehran R. Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial. Cardiovasc Res. 2020 Jun 1;116(7):e70-e72. doi:10.1093/cvr/cvaa120.

Belsey J, Savelieva I, Mugelli A, Camm AJ. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis. Eur J Prev Cardiol. 2015 Jul;22(7):837-848. doi:10.1177/2047487314533217.

Askari IV. Features of pharmacotherapy β1-adrenoblocker with activation of endothelial nitric oxide nebivolol in patients with coronary heart disease on the background of chronic heart failure (review of literature). Challenges in Modern Medicine. 2018;41(4):528-538. doi:10.18413/2075-4728-2018-41-4-528-538. (in Russian).

Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018 May;34(5):575-584. doi:10.1016/j.cjca.2017.12.005.

Koval SM, Yushko KO, Snihurska IO, et al. Relations of angiotensin-(1-7) with hemodynamic and cardiac structural and functional parameters in patients with hypertension and type 2 diabetes. Arterial Hypertension. 2019;23(3):183-189. doi:10.5603/AH.a2019.0012.

França-Silva MS, Balarini CM, Cruz JC, Khan BA, Rampelotto PH, Braga VA. Organic nitrates: past, present and future. Molecules. 2014 Sep 24;19(9):15314-15323. doi:10.3390/molecules190915314.

Boden WE, Padala SK, Cabral KP, Buschmann IR, Sidhu MS. Role of short-acting nitroglycerin in the management of ischemic heart disease. Drug Des Devel Ther. 2015 Aug 19;9:4793-4805. doi:10.2147/DDDT.S79116.

Tarkin JM, Kaski JC. Nicorandil and Long-acting Nitrates: Vasodilator Therapies for the Management of Chronic Stable Angina Pectoris. Eur Cardiol. 2018 Aug;13(1):23-28. doi:10.15420/ecr.2018.9.2.

Sirenko YuM, Torbas OO. Modern symptomatic therapy for stable angina pectoris: what to choose? Arterialʹnaâ gipertenziâ. 2019;(65-66):20-30. doi:10.22141/2224-1485.3-4.64-65.2019.177844. (in Ukrainian).

Rosendorff C, Lackland DT, Allison M, et al. Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol. 2015 May 12;65(18):1998-2038. doi:10.1016/j.jacc.2015.02.038.

Pragani MA, Desai KP, Morrone D, Sidhu MS, Boden WE. The Role of Nitrates in the Management of Stable Ischemic Heart Disease: A Review of the Current Evidence and Guidelines. Rev Cardiovasc Med. 2017;18(1):14-20. doi:10.3909/ricm0857.

Grodzinsky A, Arnold SV, Jacob D, Draznin B, Kosiborod M. The impact of cardiovascular drugs on glycemic control: A review. Endocr Pract. 2017 Mar;23(3):363-371. doi:10.4158/EP161309.RA.

Lehrke M, Marx N. Diabetes Mellitus and Heart Failure. Am J Med. 2017 Jun;130(6S):S40-S50. doi:10.1016/j.amjmed.2017.04.010.

Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016 Feb 11;352:i438. doi:10.1136/bmj.i438.

Cho YR, Ann SH, Won KB, et al. Association between insulin resistance, hyperglycemia, and coronary artery disease according to the presence of diabetes. Sci Rep. 2019 Sep 2;9(1):6129. doi:10.1038/s41598-019-42700-1.

Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019 Jun 11;73(22):2791-2802. doi:10.1016/j.jacc.2019.02.032.

Giugliano RP, Wiviott SD, Blazing MA, et al. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017 May 1;2(5):547-555. doi:10.1001/jamacardio.2017.0083.

Giugliano RP, Pedersen TR, Saver JL, et al. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 2020 May;51(5):1546-1554. doi:10.1161/STROKEAHA.119.027759.

Wójcik C. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. Postgrad Med. 2017 Nov;129(8):801-810. doi:10.1080/00325481.2017.1376570.

Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi:10.1056/NEJMoa1801174.